UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000058781 |
|---|---|
| Receipt number | R000067213 |
| Scientific Title | Pathophysiological Analysis of Esophageal Motility Disorders Using Autoantibody Biomarkers and Exploration of Novel Biomarkers |
| Date of disclosure of the study information | 2025/08/13 |
| Last modified on | 2025/08/13 00:07:20 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Pathophysiological Analysis of Esophageal Motility Disorders Using Autoantibody Biomarkers and Exploration of Novel Biomarkers
Acronym
E-MOTION (Esophageal MOtility disorders TIssue biomarkers ONe study)
Scientific Title
Pathophysiological Analysis of Esophageal Motility Disorders Using Autoantibody Biomarkers and Exploration of Novel Biomarkers
Scientific Title:Acronym
E-MOTION (Esophageal MOtility disorders TIssue biomarkers ONe study)
Region
| Japan |
Condition
Condition
Patients with esophageal motility disorders such as achalasia and diffuse esophageal spasm
Classification by specialty
| Gastroenterology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The objective of this study is to perform the MUSCAT Assay (Multiple S-cationized antigen beads array assay) using plasma from patients with esophageal motility disorders, in order to identify markers useful for the diagnosis of esophageal motility disorders.
Basic objectives2
Others
Basic objectives -Others
The objective of this study is to perform the MUSCAT Assay (Multiple S-cationized antigen beads array assay) using plasma from patients with esophageal motility disorders, in order to identify markers useful for the diagnosis of esophageal motility disorders.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The primary endpoint is to perform the MUSCAT Assay using plasma from patients with and without esophageal motility disorders and to compare the autoantibody results between the two groups.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 90 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Patients scheduled for blood tests, including those with and without esophageal motility disorders
Key exclusion criteria
Women who are pregnant or may be pregnant
Target sample size
250
Research contact person
Name of lead principal investigator
| 1st name | Masaya |
| Middle name | |
| Last name | Iwamuro |
Organization
Okayama University Hospital
Division name
Department of Gastroenterology and Hepatology
Zip code
700-8558
Address
2-5-1 Shikata-cho, Kita-ku, Okayama
TEL
086-235-7219
iwamuromasaya@yahoo.co.jp
Public contact
Name of contact person
| 1st name | Masaya |
| Middle name | |
| Last name | Iwamuro |
Organization
Okayama University Hospital
Division name
Department of Gastroenterology
Zip code
700-8558
Address
2-5-1 Shikata-cho, Kita-ku
TEL
086-235-7219
Homepage URL
iwamuromasaya@yahoo.co.jp
Sponsor or person
Institute
Okayama University Hospital
Institute
Department
Personal name
Masaya Iwamuro
Funding Source
Organization
Self-funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Okayama University IRB
Address
2-5-1 Shikata-cho, Kita-ku, Okayama
Tel
086-235-7219
iwamuromasaya@yahoo.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
None Selected
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 08 | Month | 13 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2025 | Year | 07 | Month | 25 | Day |
Date of IRB
| 2025 | Year | 07 | Month | 25 | Day |
Anticipated trial start date
| 2025 | Year | 08 | Month | 13 | Day |
Last follow-up date
| 2027 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
A medical record review will be conducted for the following items:
Patient demographics: age, sex, comorbidities, and medications
Imaging test results: CT scans, endoscopy, and esophagography
Prognosis (outcome)
Blood tests: white blood cell count, red blood cell count, platelet count, biochemical test values, tumor markers, etc.
Pathology results: histopathological findings of esophageal biopsy specimens
Management information
Registered date
| 2025 | Year | 08 | Month | 13 | Day |
Last modified on
| 2025 | Year | 08 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067213
